

RAKESH KUMAR BAGAI, MD  
**Ironwood Cancer and Research Centers**  
**Division of Oncology and Hematology**  
Skin, Sarcoma and Gastrointestinal Malignancies

**Education:**

**Hematology/Oncology Fellowship – Cleveland Clinic, Taussig Cancer Institute**  
07/01/2011 – 7/2014

**Internal Medicine Residency – Case Western Reserve University/University Hospitals Case Medical Center**  
06/24/2008 - 06/30/2011

**M.D., University of Cincinnati College of Medicine**  
08/12/2004 - 06/14/2008

**B.S./M.D. Program, John Carroll University and University of Cincinnati College of Medicine**  
08/28/2000 - 05/18/2003

**Professional Experience:**

7/15/14- Present      Ironwood Cancer & Research Centers – Medical Oncologist, Division Director of Skin and Sarcoma Malignancies

**Activities and Honors:**

Certifications:

American Board of Internal Medicine, passed 2011

Awards, Honors and Committees:

PHOENIX Magazine Top Doctor Award 2023  
Caregiver Appreciation Award - Cleveland Clinic recognition of leadership and exemplary oncology care, 2013  
Carpenter Award - University Hospitals Case Medical Center recognition of clinical excellence, 2011  
Young Investigator Award - American Transplant Congress recognition of research excellence, 2005  
John Carroll University President's Honor Award, 2000-2003  
John Huntington Scholarship, 2000-2003  
American Values Scholarship, 2000-2003

Minority Affairs Honor Award, 2000-2003  
Corporate Intern Scholarship, 2000-2003

### **Professional Memberships:**

American Society of Clinical Oncology  
American Society of Hematology  
American Medical Association, 2004-present  
Indian Student Association, 1996-present

### **Publications:**

**Bagai R**, Zhang W, Leahy P, Yin L, Ma P. CARD8/BCL-2 Cascade in Early Adaptive Drug Resistant Tumor Escape Against Targeted Inhibitors in NSCLC. *J Clin Oncol* 31, 2013 (suppl; abstr e22032). 2013 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, June 2013.

Yin L, Shi I, Zhang W, **Bagai R**, Feng Y, Ma P. Studies of Early Adaptive Resistance in Mutant-EGFR and EML4-ALK Addicted Non-Small Cell Lung Cancer in Escape Against Small Molecule Inhibitors. American Association for Cancer Research (AACR) Annual Meeting. Washington, DC, April, 2013.

**Bagai R**, Pennell N. ZEPHYR Illustrates the Perils of Testing Targeted Treatments in Unselected Non-Small-Cell Lung Cancer Patients. *Translational Lung Cancer Research*. 2013 February, 2 (1): E1-E3.

**Bagai R**, Ma P. The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal Cancer. *Current Colorectal Cancer Reports*. 2012 December; 8(4): 243-253.

**Bagai R**, Ma P. Tasisulam, an Acyl Sulfonamide Cell Cycle Inhibitor for the Treatment of Solid and Liquid Tumors. *IDrugs*. November 2012.

**Bagai R**, Ma P. Combined Treatment with MET Inhibitors and Other Therapies in Lung Cancer. *Translational Lung Cancer Research*. 2012 September; 1(3): 214-218.

Prithviraj GK, Koroukian S, Margevicius S, Berger NA, **Bagai R**, Owusu C. Patient Characteristics Associated with Polypharmacy and Inappropriate Prescribing of Medications among Older Adults with Cancer. *J Geriatr Oncol*. 2012 Jul 1;3(3):228-237. PMID: 22712030

Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, Fu P, Huang H, **Bagai R**, Jiang S, Kresak A, Howell S, VasANJI A, Flask CA, Halmos B, Koon H, Ma PC. [MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.](#) *Cancer Res.* 2011 Jul 1;71(13):4494-505. PMID: 21555370

**Bagai R**, Fan W, Ma P. ARQ-197, an Oral Small-Molecule Inhibitor of c-Met for the Treatment of Solid Tumors. *IDrugs.* 2010 Jun;13(6):404-14. PMID: 20506063

**Bagai R**, Valujskikh A, Canaday DH, Bailey E, Lalli PN, Harding CV, Heeger PS. Mouse Endothelial Cells Cross-Present Lymphocyte-Derived Antigen on Class I MHC via a TAP1- and Proteasome-Dependent Pathway. *J Immunol.* 2005 Jun 15;174(12):7711-5. PMID: 15944272

**Cleveland Clinic Taussig Cancer Institute Grand Rounds Presentation, Cleveland, OH, October 2013**  
Strategies to Overcome Resistance in Non-Small Cell Lung Cancer

**University Hospital Case Medical Center Research Day, Abstract and Poster Presentation, University Hospitals Case Medical Center, Cleveland, Ohio, May 2010**  
Role of BCL-2 Antiapoptotic Protein in Promoting Tumor Functional Resistant Evasion Against Targeted Inhibitors in Non-Small Cell Lung Cancer

**American Transplant Congress Annual Meeting, Abstract and Oral Presentation, Washington State Convention Center, Seattle, Washington, May 2005**  
Mouse endothelial cells cross present lymphocyte-derived antigen on class I MHC via a TAP1- and proteasome-dependent pathway.

### **Research Trials:**

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.

### **Other Activities:**

Tennis, chess, yoga, fluent in Hindi